# A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

> **NCT06088979** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tourmaline Bio, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** TOUR006 - 20 MG
- **OTHER:** Placebo
- **DRUG:** TOUR006 - 50 MG

## Key facts

- **NCT ID:** NCT06088979
- **Lead sponsor:** Tourmaline Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088979, "A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06088979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*